Quarterly report pursuant to Section 13 or 15(d)

Revenue and Accounts Receivable (Tables)

v3.5.0.2
Revenue and Accounts Receivable (Tables)
9 Months Ended
Sep. 30, 2016
Receivables [Abstract]  
Schedule of Revenue by Service Type
Revenue by service type for the three and nine months ended September 30, 2016 and 2015 is comprised of the following (in thousands): 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Biopharma Services
$
3,805

 
$
2,608

 
11,374

 
$
8,614

Clinical Services
2,687

 
1,150

 
7,685

 
3,274

Discovery Services
258

 
243

 
760

 
668

 
$
6,750

 
$
4,001

 
$
19,819

 
$
12,556

Schedule of Accounts Receivable by Service Type
Accounts receivable by service type at September 30, 2016 and December 31, 2015 consists of the following (in thousands): 

September 30,
2016
 
December 31,
2015
Biopharma Services
$
5,369

 
$
3,238

Clinical Services
8,607

 
3,733

Discovery Services
375

 
314

Allowance for doubtful accounts
(672
)
 
(664
)

$
13,679

 
$
6,621


Allowance for Doubtful Accounts (in thousands)
Balance, December 31, 2015
$
664

Bad debt expense
8

Balance, September 30, 2016
$
672

Schedule of Clinical Services Revenue (As a Percent of Total Revenue)
The breakdown of our Clinical Services revenue (as a percent of total revenue) is as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Medicare
14%
 
12%
 
13%
 
8%
Other insurers
21%
 
7%
 
20%
 
7%
Other healthcare facilities
5%
 
9%
 
6%
 
8%
 
40%
 
28%
 
39%
 
23%